September 17, 2025

Tumor Treating Fields An Innovative Therapy for Glioblastoma and Other Solid Tumors

Explore how Tumor Treating Fields therapy is revolutionizing glioblastoma treatment and enhancing patient outcomes, as discussed by Novocure experts.

JADPRO

September 11, 2025

Underlying Mechanisms of Chemoresistance in AML

Researchers have discovered that an isoform of the transcription factor RUNX1 orchestrates chemoresistance in patients with acute myeloid leukemia (AML), according to findings published in Blood Cance...

The ASCO Post

September 10, 2025

Bridging the Gap in Geriatric Oncology Education: A Global Imperative

As the global population ages, oncology faces an urgent challenge: ensuring that health-care professionals are adequately trained to address the unique complexities of cancer care for older adults. De...

The ASCO Post

September 10, 2025

OHSU Knight Cancer Institute Receives $2 Billion Commitment From Phil and Penny Knight

Phil Knight, co-founder of Nike, and Penny Knight announced a record-breaking $2 billion gift to the Oregon Health & Science University’s (OHSU) Knight Cancer Institute to transform the future of ...

The ASCO Post

September 10, 2025

John C. Byrd, MD, FASCO, Named UPMC Hillman Cancer Center Director

An internationally lauded researcher and clinical specialist in hematologic malignancies has been appointed Director of UPMC Hillman Cancer Center, effective November 2025.

The ASCO Post

September 10, 2025

The Future of Cell Therapy: Optimizing the CAR to the Disease in B-Cell Malignancies

Explore the evolution of therapies for B-cell malignancies and the potential of dual-targeted CAR T-cell approaches to enhance patient outcomes. - Dr. Shah

The ASCO Post

September 05, 2025

Drivers of Hematology and Oncology Care Team Staff Satisfaction

A comprehensive study reveals the critical role of communication and team culture in enhancing job satisfaction among oncology healthcare professionals amid evolving cancer care practices.

JADPRO

September 02, 2025

Body Image and Quality of Life in Advanced Breast Cancer: The State of the Science

Explore the intricate relationship between body image and quality of life in advanced breast cancer patients, revealing gaps in existing research and highlighting the need for enhanced psychosocial support.

JADPRO

September 02, 2025

RP1 Plus Nivolumab in Anti–PD-1–Resistant Advanced Melanoma

When combined with nivolumab, RP1 induced systemic responses in patients with advanced melanoma who have failed to respond to prior anti–PD-1 therapy, according to findings from the phase I/II IGNYTE ...

The ASCO Post